drugset / Trial / NCT00553800
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
Phase 2
Completed
32 enrolled
Fox Chase Cancer Center
Genentech, Inc. · collabOSI Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
Timeline
- Start
- 2007-07-05
- Primary completion
- 2011-01-12
- Completion
- 2011-06-01
Publications
- Background Phase II study of bevacizumab and erlotinib in treatment-naïve elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC). H. Borghaei, R. Mehra, M. M. Millenson, H. Tuttle, K. Ruth, A. J. Magdalinski, D. M. Mintzer, J. W. Lee, G. R. Simon, and C. J. Langer Journal of Clinical Oncology 2010 28:15_suppl, e18019-e18019
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |